Urinary Biomarkers of OI Pathobiology

Osteogenesis Imperfecta Clinical Trial

Official title:

Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02531087
• Other study ID #: 37358
• Status: Active, not recruiting
• Start date: September 2015
• Est. completion date: December 2025

Study information

• Verified date: November 2023
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Description:

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. People with OI also often have problems with the spine. The spine problems include compression fractures and scoliosis (a curvature of the spine). DI is characterized by grey or brown teeth that may chip and wear down and break easily. In addition to weak teeth, the teeth in the upper jaw may not match up with the teeth in the lower jaw.

Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. In the past decade, it was discovered that in about 5% of people with OI it is in another gene. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: December 2025
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• To be able to participate, you must:

Be enrolled in The Longitudinal Study of OI (NTC #02432625) and have one of the following genetic mutations:

• glycine substitution mutations in COL1A1 or COL1A2

• haploinsufficient mutation in COL1A1 or COL1A2

• mutations in CRTAP, PPIB, or LEPRE1

• mutations in FKBP10 or SERPINH1

• mutations in (SERPINF1, WNT1, or IFITM5)

• dominant negative glycine substitutions and haploinsufficient mutations in COL1A1, and COL1A2

If you are serving as a control, you must not be related to an individual with OI.

Exclusion Criteria:

• You cannot participate if:

• You are unable to comply with the sample collection schedule.

• You are related to one of the OI subjects and would like to serve as a control subject.

• You have vertebral instrumentation or spinal deformities where we cannot assess lumbar spine aBMD.

• You have a history of recent fracture (< 3 months).

• You have serum creatinine above 1x upper limits of normal.

• You have abnormal kidney function.

• You are using Minoxidil.

• You are unable to provide a urine sample readily.

Related Conditions & MeSH terms

• Osteogenesis Imperfecta

Locations

Country	Name	City	State
Canada	Shriners Hospital for Children	Montreal	Quebec
United States	Baylor College of Medicine	Houston	Texas
United States	University of California Los Angeles	Los Angeles	California
United States	Shriners Hospital for Children	Milwaukee	Wisconsin
United States	Hospital for Special Surgery	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Oregon Health Science University	Portland	Oregon

Sponsors (4)

Lead Sponsor	Collaborator
Baylor College of Medicine	Shriners Hospitals for Children, University of Nebraska, University of Washington

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HP/LP Ratio	The endpoint will be to compare the HP/LP ratio in OI patients with collagen overmodification (dominant negative mutations in COL1A1, COL1A2, and biallelic mutations in CRTAP, LEPRE1, PPIB) to those without overmodification (FKBP10, SERPINH1, IFITM5, SERPINF1, WNT1, and haploinsufficient mutations in COL1A1 and COL1A2).	5 Years
Secondary	HP/LP ratio	The endpoint would be the HP/LP ratio in those with dominant negative type I collagen mutations vs. those with mutations in P3H complex.	5 Years